COPD exacerbation rates in placebo arms of clinical trials declined by roughly 6.7% per year, or 50% per decade, between the late 1990s and 2019.
Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial
1 Pith paper cite this work. Polarity classification is still indexing.
1
Pith paper citing it
fields
stat.AP 1years
2019 1verdicts
CONDITIONAL 1representative citing papers
citing papers explorer
-
Decline of COPD exacerbations in clinical trials over two decades -- a systematic review and meta-regression
COPD exacerbation rates in placebo arms of clinical trials declined by roughly 6.7% per year, or 50% per decade, between the late 1990s and 2019.